theMednetRegister

ASCO 2022   

Questions discussed in this category

How does one interpret the LUMINA trial in the FLORENCE APBI ERA?
While I am encouraged by the results of the LUMINA trial with respect to identifying patients who are less likely to benefit from radiation therapy wh...
5 Answers available
Will you offer cetuximab or panitumumab with FOLFOX in patients with metastatic left sided RAS/BRAF WT MSS colon cancer instead of bevacizumab?
Do the overall survival results of PARADIGM presented at ASCO 2022 change the standard of care?
3 Answers available
In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?
J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024
2 Answers available
What are your top takeaways in Head & Neck Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...
2 Answers available
What are your top takeaways in Gynecologic Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...
2 Answers available
What are your top takeaways in Melanoma from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...
1 Answer available
How do you now approach treatment sequencing in MM in light of the DETERMINATION trial data?
Do the results change your clinical practice?
2 Answers available
What are your top takeaways in Thoracic Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
6 Answers available
What are your top takeaways in GI Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
5 Answers available
What are your top takeaways in Breast Cancer from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...
12 Answers available
What are your top takeaways from ASCO GU 2022?
6 Answers available


Papers discussed in this category

Lancet Oncol, 2014 Jul 31
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med,
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med, 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
J Natl Compr Canc Netw, 2021 Mar 24
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
N Engl J Med,
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med, 2022 Jun 05
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
N Engl J Med, 2022 Jun 04
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
J Clin Oncol, 2022 Jun 06
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
International journal of radiation oncology, biology, physics, 2014-03-01
Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.
J Clin Oncol, 2017 Dec 8
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
N Engl J Med, 2020 Sep 18
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
BMC Cancer, 2021 May 27
Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma.
N Engl J Med, 2022 Jun 03
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.
J Clin Oncol, 2022 Jun 03
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The New England journal of medicine, 2019-05-30
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Blood,
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
N Engl J Med, 2022 Jun 05
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Pediatr Blood Cancer, 2022 Oct 02
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Clin Cancer Res, 2023 Jan 09
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.
Breast Cancer Res Treat, 2020 Jul
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
JCO Oncol Pract, 2021 Aug
Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation.
Eur. J. Cancer, 2015-03-01
Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial.
J Clin Oncol, 2022 Jun 06
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
N Engl J Med,
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.